Novartis CEO on 2Q Profit Beat, Investing in Pipeline

Summary

Novartis CEO Vas Narasimhan discusses the company's strong Q2 performance, reaffirmed full-year guidance, and strategy to navigate patent expirations. He highlights a robust pipeline of oncology and cardiovascular drugs, upcoming phase 3 readouts for remibrutinib and deldesiran that could upgrade mid-term guidance, and an underappreciated growth story. He also addresses drug pricing pressures globally, noting headwinds in Europe and potential opportunities in Japan, and outlines the company's acquisition strategy focused on adding technology platforms and late-stage assets.

• Novartis beat Q2 estimates and reaffirmed full-year guidance, citing a tale of two halves with patent expirations in H1 and growth in H2.
• CEO expects sustained 5-6% annual growth through 2030, supported by oncology drugs (Kisqali, Pluvicto) and cardiovascular medicine (Leqvio).
• Key pipeline catalysts include phase 3 readouts for remibrutinib in multiple sclerosis and deldesiran for DM1, which could lead to guidance upgrades.
• CEO believes Wall Street is underestimating the company's growth potential from current assets and pipeline.
• Radio ligand therapy infrastructure creates a competitive moat, with a potential $25-30 billion segment.
• Drug pricing dynamics: Most Favored Nation agreements with the US are factored in, but European policies (e.g., Germany) pose access headwinds.
• M&A strategy favors smaller bolt-on deals that add technology platforms and late-stage assets in core therapeutic areas.